The central importance of the Th17/IL-17 pathway in the pathogenesis of psoriasis and other inflammatory conditions has been confirmed by the impressive clinical efficacy following therapeutic intervention with antibodies neutralizing and blocking IL-17/IL-17 receptor interaction (7, 15–17). Here, IL17A is linked to psoriasis.